CT增强检查评估埃克替尼治疗非小细胞肺癌的疗效

《CT增强检查评估埃克替尼治疗非小细胞肺癌的疗效》由会员上传分享，免费在线阅读，更多相关内容在行业资料-天天文库。

1、CT增强检查评估埃克替尼治疗非小细胞肺癌的疗效陈红1，杨照环1，刘海霞3，肖颖1，任淑华2，王海波1，刘华群1，房芳1唐山市工人医院，河北唐山063000,1肿瘤科2胸外科3影像诊断科[摘要]目的探讨CT动态增强检查评估埃克替尼治疗非小细胞肺癌（NSCLC）疗效的可行性及临床应用价值。方法回顾性分析经病理证实的晚期NSCLC患者经分子靶向药物埃克替尼治疗前后的CT动态增强检查资料及临床资料，将患者按照RECIST标准分为缓解组和未缓解组，测量并比较两组治疗前1周内及治疗后1月病灶CT动态增强检查结果。结果分析

2、测量45例患者，其中缓解组26例，未缓解组19例；两组患者治疗前病灶密度及强化程度无统计学差异，p﹥0.05；缓解组患者治疗后病灶密度及强化程度均减低，差异有显著统计学意义，p=0.000；未缓解组治疗后CT密度及强化程度较治疗前略增高，但差异无统计学意义，p﹥0.05。缓解组治疗后病灶密度及强化程度均低于未缓解组，差异有统计学意义，p﹤0.05。结论NSCLC经过埃克替尼治疗后定量分析病灶密度变化及强化程度可以为疗效评估提供参考。[关键词]强化CT;非小细胞肺癌;埃克替尼;疗效评价TheValueofCon

3、trast-EnhancedCTinEvaluatingCurativeEffectofConmanaforNon-SmallCellLungCancer【Abstract】Purpose　Toevaluatethevalueofcontrast-enhancedCTimagingindiagnosingtherapeuticeffectofnon-smallcelllungcancer.MaterialsandMethods　Forty-fivepatientswithnon-smallcelllungca

4、ncerprovedhistologicallyunderwentcontrast-enhancedCTscanningbeforeandaftertherapy.Alldatawereautomaticallyanalyzedandchangesofeachparameterbeforeandaftertherapywerecompared.Results　AccordingtotheresponsetotherapybasedonRECISTandfollowedupfor3months,26outof4

5、5patientsobtainedeffectivetreatment,and19patientsobtainedineffectivetreatment.Themeandensityandenhancementextentoflesionsfor45patientsobtainedeffectivetreatmentbeforetreatmentwerenostatisticallydifferencethanthoseobtainedineffectivetreatment(p﹥0.05).Aftertr

6、eatment,themeandensityandenhancementextentoflesionsfor26patientsobtainedeffectivetreatmentweresignificantlydecreasedthanthosebeforetreatment(p=0.000).Noobviousdifferenceinanyparameterfor16patientsobtainedineffectivetreatmentwasobservedbeforeandaftertreatmen

7、t(P＞0.05).Themeandensityandenhancementextentoflesionsforpatientsobtainedeffectivetreatmentweresignificantlydecreasedthanthosepatientsobtainedineffectivetreatment(p﹤0.05).Conclusion　Contrast-enhancedCTscanningcanquantitativelyassessthechangesoflesionsbeforea

8、ndaftertreatmentofnon-smallcelllungcancer,furtherearlypredicttheoutcomeandhassignificantvalueininspectingcurativeeffect.【Keywords】Contrast-enhancedCT;Non-small-celllungcancer;lcotinib;Effectevaluation肺